3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase NA
1
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
22
Breast Neoplasms
19
Lymphoma
14
Sarcoma
13
Lymphoma, Non-Hodgkin
9
Lymphoma, Follicular
8
Lymphoma, B-Cell
8
Hodgkin Disease
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Mantle-Cell
5
Immunoblastic Lymphadenopathy
5
Ovarian Neoplasms
4
Neoplasms
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Hepatocellular
4
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Primary Effusion
3
Chondrosarcoma
3
Triple Negative Breast Neoplasms
2
Solitary Fibrous Tumors
2
Sarcoma, Clear Cell
2
Plasmablastic Lymphoma
2
Osteosarcoma
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Liver Neoplasms
2
Interventions
tremelimumab
1
poly(I).poly(c12,U)
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
genexol-PM
1
abagovomab
1
Topotecan
1
Paclitaxel
1
Oxaliplatin
1
MOC31PE immunotoxin
1
LY-2157299
1
Introns
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Drug Therapy
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Celecoxib
1
Capecitabine
1
Bevacizumab
1
AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase
1
Acids
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Peritoneal Neoplasms
×
Doxorubicin
×
Clear all
NCT02604784
2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2
Completed
105 enrolled